Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-23T12:31:59.589Z Has data issue: false hasContentIssue false
  • English
  • Français

Monoclonal antibodies in bone marrow transplantation

Published online by Cambridge University Press:  05 December 2011

G. Janossy
G. Janossy
Affiliation:
Department of Immunology, Royal Free Hospital, School of Medicine, London NW3 2QG
Get access

Synopsis

When bone marrow (BM) is taken, cells in suspension are accessible to antibodies. BM transplantation is therefore an ideal situation for using monoclonal antibodies in therapy. These applications include prevention of graft versus host disease by eliminating T cells from allogeneic BM marrow, and the elimination of residual malignant cells from autologous bone marrow. Me Ab-s are currently tested for the removal of residual leukaemic cells in the common form of acute lymphoblastic leukaemia (ALL) and in thymic ALL. Encouraging experiments also indicate that the removal of B leukaemias/lymphomas from the BM will also be feasible.

The review summarises the various ways Ab-s can damage coated ‘unwanted’ cells (opsonisation, complement mediated lysis, and Ab-s coupled to toxins), and the principles for selecting Me Ab-s for BM transplantation.

Type
Research Article
Information
Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences , Volume 81 , Issue 4: Clinical applications of monoclonal antibodies , 1982 , pp. 233 - 245
Copyright
Copyright © Royal Society of Edinburgh 1982

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abramson, C. S., Kersey, J. H. and LeBien, T. W. 1981. A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage. J. Immun., 126, 83–88.CrossRefGoogle ScholarPubMed
Bradstock, K. F., Janossy, C, Pizzolo, G., Hoffbrand, A. V., McMichael, A., Pilch, J. R., Milstein, C., Beverley, P. and Bollum, F. J. 1980. Subpopulations of normal and leukaemic human thymocytes: an analysis with the use of monoclonal antibodies. J. Natn. Cancer Inst. 65, 33–42.Google ScholarPubMed
Caligaris-Cappio, F., Gobbi, M., Bofill, M. and Janossy, G. 1982. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukaemia. J. Exp. Med. 155, 623–628.CrossRefGoogle Scholar
Clavell, L. A., Lipton, J. M., Bast, R. C., Kudisch, M., Pesando, J., Schlossman, S. F. and Ritz, J. 1981. Absence of common ALL antigen on normal bipotent myeloid, erythroid and granulocyte progenitors. Blood 58, 333–336.CrossRefGoogle ScholarPubMed
Cosimi, A. B. 1981. The clinical value of anti-lymphocyte antibodies. Transpl. Proc. 13, 462–468.Google Scholar
Cosimi, A. B., Colvin, R. B., Burton, R. C., Rubin, R. H., Goldstein, G., Kung, P. C., Hansen, W. P., Delmonico, F. L. and Russell, P. S. 1981. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. New. Engl. J. Med. 305, 308–314.CrossRefGoogle ScholarPubMed
Deng, C, Chia, J., Terasaki, P. and Billing, R. 1982. Monoclonal antibody specific for human T acute lymphoblastic leukaemia. Lancet I, 10–11.CrossRefGoogle Scholar
Fabre, J. 1982. Monoclonal anti-lymphocyte antibodies as immunosuppressive reagents for clinical practice. Proc. Roy. Soc. Edinb. 81B.Google Scholar
Gilmore, M. J. M. L., Prentice, H. G., Blacklock, H. A., Ma, D. D. F., Janossy, G. and Hoffbrand, A. V. 1982. A technique for rapid isolation of bone marrow mononuclear cells using ficoll-metrizoate and the IBM-2991 blood cell processor. Br. J. Haemal. 50, 619–626.CrossRefGoogle ScholarPubMed
Gorin, N. C., David, R., Stachowiak, J., Salmon, Ch., Petit, J. C., Parlier, Y., Najman, A. and Duhamel, G. 1981. High dose chemotherapy and autologous bone marrow transplantation in acute leukaemias, malignant lymphomas and solid tumours: A study of 23 patients. Eur. J. Cancer 17, 557–568.CrossRefGoogle ScholarPubMed
Granger, S. M., Janossy, G.. Francis, G., Blacklock, H., Poulter, L. W. and Hoffbrand, A. V. 1982. Elimination of T lymphocytes from human bone marrow with monoclonal anti-T antibodies and cytolytic complement. Br. J. Haemal. 50, 367–374.CrossRefGoogle Scholar
Granger, S., Janossy, G., Tidman, N., Ashley, J., Crawford, D. H., Koubek, K., Francis, G., Prentice, H. G., Hoffbrand, A. V., Kung, P. C. and Goldstein, G. 1981. Standardisation of monoclonal antibodies for human bone marrow transplantation. In Leukaemia Markers, ed. Knapp, W., pp. 390–404. London: Academic Press.Google Scholar
Greaves, M. F., Brown, G., Rapson, N. T. and Lister, T. A. 1975. Antiserum to acute lymphoblastic leukaemia cells. Clin. Immun. Immunopath. 4, 67–84.CrossRefGoogle Scholar
Greaves, M. F. and Janossy, G., 1978. Patterns of gene expression and the cellular origins of human leukaemias. Biochim. Biophys. Ada 516, 193–230.Google ScholarPubMed
Greaves, M. F., Paxton, A., Janossy, G., Pain, C Johnson, S. and Lister, T. A. 1980. Acute lymphoblastic leukaemia associated antigen. III. Alterations in expression during treatment and relapse. Leukaemia Res. 4, 1–14.CrossRefGoogle Scholar
Greaves, M. F., Rao, J., Hariri, G., Verbi, W., Catovsky, D., Kung, P. C. and Goldstein, G. 1981. Phenotypic heterogeneity and cellular origins of T cell malignancies. Leukaemia Res. 5, 281–299.CrossRefGoogle ScholarPubMed
Hamblin, T. J., Abdul-Ahad, A. K., Gordon, J., Stevenson, F. K. and Stevenson, G. T. 1980. Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobin idiotypes on the cell surface. Br. J. Cancer 42, 495–502.CrossRefGoogle Scholar
Hansen, J. A., Martin, P. J., Kamoun, M., Torok-Storb, B., Newman, W., Nowinski, R. C. and Thomas, E. D. 1981. Monoclonal antibodies recognizing human Tcell: potential role for preventing GvH reactions following allogeneic marrow transplantation. Transpl. Proc. 13, 113–1137.Google Scholar
Hoffman-Fezer, G., Thierfelder, S., Rodt, H., Kummer, U., Doxiadis, I., Stunkel, K. and Eulitz, M. 1981. Diagnostic and therapeutic applications of antisera to membrane antigens. In Leukaemia Markers, ed. Knapp, W., pp. 405–418. London: Academic Press.Google Scholar
Janossy, G., Cosimi, A. B. and Goldstein, G. 1982a. Monoclonal anti-human lymphocyte antibodies: potential value in immunosuppression and bone marrow transplantation. In Monoclonal Antibodies in Clinical Medicine, ed. McMichael, A. and Fabre, J. W. London: Academic Press.Google Scholar
Janossy, G., Montano, L., Selby, W. S., Duke, O., Panayi, G., Lampert, I., Thomas, J. A., Granger, S., Bofill, M., Tidman, N., Thomas, H. C. and Goldstein, G. 1982b. T cell subset abnormalities in tissue lesions developing during autoimmune disorders, viral infection and graft versus host disease. J. Clin. Immun. in press.Google Scholar
Janossy, G., Tidman, N., Papageorgiou, E. S., Kung, P. C. and Goldstein, G. 1981. Distribution of T lymphocyte subsets in the human bone marrow and thymus–an analysis with monoclonal antibodies. J. Immun. 126, 1608–1613.CrossRefGoogle ScholarPubMed
Kempshed, J., Sitschi, J., Asser, U., Sutherland, R. and Greaves, M. F. 1982. Monoclonal antibodies defining markers with apparent selectivity for particular haematopoietic cell types may also detect antigens on cells of neural crest origin. Hybridoma, 1, 109–123.CrossRefGoogle Scholar
Kersey, J. H. 1982. Personal communication.Google Scholar
Kung, P. C., Talle, M. A., DeMaria, M., Butler, M., Lifter, J. and Goldstein, G. 1980. Stategies for generating monoclonal antibodies defining human T lymphocyte differentiation antigens. Transpl. Proc. 12, 141–146.Google Scholar
LeBien, T. W., Brasham, C. J., Abramson, C. S., Frenzel, E. M., Bollum, F. J. and Kersey, J. H. 1981. Studies of human lymphopoiesis with monoclonal antibodies Ba-1 and BA-2. In Leukaemia Markers, ed. Knapp, W., pp. 81–84. London: Academic Press.Google Scholar
Linch, D. C., Beverley, P. C. L., Newland, A. C. and Turnbull, A. L. 1981. Treatment of T cell proliferation with monoclonal antibody. Lancet, II 524.CrossRefGoogle Scholar
Liszka, K., Majdic, O., Bettelheim, P. and Knapp, W. 1981. A monoclonal antibody (VIL-A1) reactive with – common acute lymphatic leukaemia cells. In Leukaemia Markers, ed. Knapp, W., pp. 61–64. London: Academic Press.Google Scholar
Martin, P. J., Hansen, J. A., Siadak, A. W. and Nowinski, R. C. 1981. Monoclonal antibodies recognizing human T lymphocytes and malignant human B lymphocytes: a comparative study. J. Immun. 127, 1920–1926.CrossRefGoogle Scholar
Metzgar, R. S., Borowitz, M. J., Jones, N. H. and Dowell, B. L. 1981. The distribution of common acute lymphoblastic leukaemia antigen (CALLA) in non-hematopoietic tissues. J. Exp. Med. 154,1249–1254.CrossRefGoogle Scholar
Miller, R. A. and Levy, R. 1981. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet II, 226–230.CrossRefGoogle Scholar
Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Lufe, D. W., Antiman, K. H. and Schlossman, S.F. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. Cancer Res. 40, 3147–3154.Google ScholarPubMed
Prentice, H. G., Blacklock, H. A., Janossy, G., Bradstock, K. F., Skeggs, D., Goldstein, G. and Hoffbrand, A. V. 1982. Use of the anti-T monoclonal antibody OKT3 for prevention of acute graft versus host disease (GvHD) in allogeneic bone marrow transplantation for acute leukaemia. Lancet in press.CrossRefGoogle Scholar
Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H. and Schlossman, S. F. 1980. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukaemic lymphoblasts of Tcell lineage. Proc. Sam. Acad. Sci. U.S.A. 77, 1588–1592.CrossRefGoogle ScholarPubMed
Ritz, J., Pesando, J. M., NotisMcConarty, J., Lazarus, H. and Schlossman, S. F. 1980a. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature, Lond. 283, 583.CrossRefGoogle ScholarPubMed
Ritz, J., Pesando, J. M.. Notis-McConarty, J. and Schlossman, S. F. 1980b. Modulation of human acute lymphoblastic leukaemia antigen induced by monoclonal antibody in vitro. J. Immun. 125, 1506–1514.CrossRefGoogle ScholarPubMed
Ritz, J., Pesando, J. M., Sallan, S. E., Clavell, L. A., Notis-McConarty, J., Rosenthal, P. and Schlossman, S. F. 1981. Serotherapy of acute lymphoblastic leukaemia with monoclonal antibody. Blood 58, 141–152.CrossRefGoogle ScholarPubMed
Rosenberg, S. A. and Terry, W. D. 1977. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25, 323–388.CrossRefGoogle Scholar
Stashenko, P., Nadler, L. M., Hardy, R. and Schlossman, S. F. 1980. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125, 1678–1685.CrossRefGoogle ScholarPubMed
Tax, W. J. M., Willems, H. W., Kibbelaar, M. D. A., de Groot, J., Capel, P. J. A., de Waal, R. M. W., Reekers, P. and Koene, R. A. P. 1981. Monoclonal antibodies against human thymocytes and T lymphocytes. Proc. XXIX Annual Colloquium Protides of the Biological Fluids, Brussels, 4–7 May 1981.Google Scholar
Thomas, E. D., Flournoy, N., Buckner, C. D., Clift, R. A., Fefer, R. A., Neiman, P. E. and Storb, R. 1977. Cure of leukaemia by marrow transplantation. Leukaemia Res. 1, 67–70.CrossRefGoogle Scholar
Thorpe, P. 1982. Monoclonal antibody-toxin conjugates. In Monoclonal Antibodies in Clinical Medicine, ed. McMichael, A. and Fabre, J. London: Academic Press.Google Scholar
Vallera, D. A., Soderling, C. B., Carlson, G. J. and Kersey, J. H. 1981. Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1, 2 or complement or antibody alone. Transplantation 31, 218–222.CrossRefGoogle ScholarPubMed
Van Wauve, J. P., De Mey, J. R. and Gossens, J. G. 1980. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immun. 124, 2708–2713.CrossRefGoogle Scholar
Verbi, W., Greaves, M. F., Koubek, K., Janossy, G., Stein, H., Kung, P. C. and Goldstein, G. 1982. OKT11 and OKT11A: monoclonal antibodies with pan T reactivity which block sheep erythrocyte ‘receptors’ on T cells. Eur. J. Immun. 12, 81–86.CrossRefGoogle Scholar
Vines, R. L.,Coleman, M. S. and Hutton, J. J. 1980. Reappearance of terminal deoxynucleotidyl transferase containing cells in rat bone marrow following corticosteroid administration. Blood 56, 501–509.CrossRefGoogle ScholarPubMed
Vitetta, E. S., Krolick, K. A. and Uhr, J. W. 1982. Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immun. Rev. 62, in press.CrossRefGoogle ScholarPubMed
Wood, E., Kersey, J. H., LeBien, T., Greaves, M. F. and Janossy, G. 1982. Use of anti-ALL antibody combinations to eliminate residual leukaemia from bone marrow, manuscript in preparation.Google Scholar